May 6 (Reuters) - Fusion Pharmaceuticals Inc FUSN.O :
* FUSION PHARMACEUTICALS ANNOUNCES CLINICAL COLLABORATION WITH MERCK TO EVALUATE FUSION'S TARGETED ALPHA THERAPY (TAT) IN COMBINATION WITH MERCK'S KEYTRUDA® (PEMBROLIZUMAB) IN PATIENTS WITH SOLID TUMORS EXPRESSING IGF-1R